Hormona adrenocorticotropa en pacientes con síndrome de West y progresión al síndromedeLennox-Gastaut

Patricia Campos-Olazabal, Yamilee Hurtado-Roca, S. Marcela Montúfar-Crespoc

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

Resumen

Background: This paper will evaluate the use of adrenocorticotropic hormone as a therapy modality for West syndrome and the time required for development of the severely progressive form of West syndrome (LGS, Lennox-Gastaut syndrome). There is little data on this condition for our population. Material and Methods: This is a cohort review in which 139 patient records were evaluated in two pediatric units in Lima, Peru; and they were analyzed between 2000 and 2010. All patients who met the following criteria were included in the study: massive spasms, delayed psychomotor development, and hypsarrhythmia in electroencephalogram (EEG) tracing. Adrenocorticotropic hormone was administered to a group of patients as post-diagnosis therapy. The follow-up period for these patients was 10 years. Results: The hazard ratio (HR) for progression to Lennox-Gastaut Syndrome in patients using adrenocorticotropic hormone was 0.45 (95% CI: 0.24-0.83, p= 0.011) compared to those without adrenocorticotropic hormone. Adjusted RR for progression to Lennox-Gastaut Syndrome for all variables studied (age of onset, sex, frequency of seizures, etiology, and time from diagnosis to therapy initiation) in patients who used adrenocorticotropic hormone was 0.56 (95% CI 0.29 to 0.08, P= 0.085) compared with those without adrenocorticotropic hormone. Conclusions: The use of adrenocorticotropic hormone in patients with West syndrome could protect against progression to Lennox-Gastaut syndrome. We consider this supports the evidence found in populations similar to ours, and we believe this finding could be confirmed with clinical trials.

Título traducido de la contribuciónAdrenocorticotropic hormone in patients with West syndrome and progression to Lennox-Gastaut syndrome
Idioma originalEspañol
Páginas (desde-hasta)466-471
Número de páginas6
PublicaciónRevista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
Volumen14
N.º4
DOI
EstadoPublicada - oct. 2021

Palabras clave

  • Adrenocorticotropic Hormone
  • Epilepsy
  • Lennox-Gastaut Syndrome

Huella

Profundice en los temas de investigación de 'Hormona adrenocorticotropa en pacientes con síndrome de West y progresión al síndromedeLennox-Gastaut'. En conjunto forman una huella única.

Citar esto